Last updated: June 7, 2026
Cystografin Dilute suppliers: Who manufactures and supplies cysteamine (meglumine cysteinate) contrast products?
Cystografin Dilute is a branded iodinated urinary tract contrast used for radiographic imaging of the bladder and urinary tract. Supplier coverage is typically split between (1) the brand owner’s commercial distributor network, (2) contract manufacturers and packaging sites supplying “dilute” presentation, and (3) parallel importers where permitted.
Supplier map (commercially relevant):
- Brand owner / US commercialization channel: typically provides the US-labeled product through authorized wholesalers/distributors.
- Authorized wholesalers/distributors: source inventory directly from the labeler, then sell to hospitals, clinics, and procurement groups.
- Repackagers/parallel importers (where applicable): can supply alternate channels if allowed by jurisdiction and labeling requirements.
No patent or Orange Book status is provided because the requested topic is “Suppliers,” and no drug substance identifiers, labeler name, NDC, dosage strength, or country were supplied to anchor supplier identification to specific manufacturing sites and distribution entities.
Who supplies Cystografin Dilute to hospitals, pharmacies, and distributors in the US?
Featured answer: Cystografin Dilute is supplied through the brand’s authorized distribution network and wholesalers that buy from the US labeler.
Distribution roles
- Labeler (brand owner): controls product distribution rights and typically supplies directly to major wholesalers.
- Wholesalers: major GPO and retail-channel distributors stock the branded concentrate and/or dilute-form presentation depending on procurement contracts.
- Institutional procurement: hospitals typically source from GPO-approved wholesalers; inventory availability can vary by lot due to manufacturing/packaging cycles.
What controls availability
- Manufacturing run schedules for the dilute presentation (solution formulation and final fill).
- Packaging capacity for the dilute container format (unit size and kit configuration).
- Regulatory release cadence by manufacturer and QA disposition in the relevant market.
Which companies make “Cystografin Dilute” (manufacturing sites and contract labs)?
Featured answer: The manufacturer is the company listed as the drug product’s manufacturer on the US label and/or corresponding regulatory listing; contract manufacturers may produce the finished solution or perform fill-finish and packaging.
How “dilute” products are typically sourced
- Finished product manufacturer: produces the solution at scale, then releases finished goods.
- Fill-finish/secondary packaging: contract packaging partners often handle final container filling, labeling, and kit assembly for “dilute” presentations.
What defines the “dilute” supplier set
- The exact NDC and presentation format determine the finished-goods manufacturer and packaging site. Without those identifiers, supplier attribution cannot be tied to specific legal entities and manufacturing locations.
What distributors carry Cystografin Dilute (wholesaler and GPO channel coverage)?
Featured answer: Wholesaler coverage depends on which NDC and presentation is stocked; hospitals typically buy through major distributors that carry branded injectables/contrast media and supply via GPO channels.
Procurement channel patterns
- GPO-driven tendering: drives which wholesalers are preferred.
- Direct purchase arrangements: some institutions buy directly from an approved distributor with standing agreements.
- Lot-level substitution: if a dilute presentation is constrained, substitution can occur at the distributor level for alternate pack sizes or concentration forms, subject to label/regulatory constraints.
How do suppliers differ by country for Cystografin Dilute?
Featured answer: Supplier sets differ by regulator and labeling market; the labeler and authorized distributors in the destination country control distribution.
Key country-level determinants
- Brand authorization (licensing) under local medicine agencies.
- Tender/insurer formularies that select specific distributors.
- Import permissions where the product is not locally produced.
What generic or alternative contrast products compete for the same supply chain?
Featured answer: Competitive supply chains include other iodinated urinary tract contrast agents used for cystography and related imaging; procurement often shifts between brands based on availability.
Substitution risk for supply
- If Cystografin Dilute is constrained, providers often switch to an alternative iodinated contrast agent with compatible imaging indications and administration route, subject to local protocol and radiology department standards.
Key Takeaways
- Supplier coverage for Cystografin Dilute is driven by the labeler’s authorized distribution network and the specific NDC/presentation’s listed finished-goods manufacturer.
- “Dilute” presentation adds a fill-finish and packaging layer, so supplier attribution depends on the exact marketed configuration.
- Competitive procurement can shift quickly to alternative iodinated urinary contrast agents if the dilute product is scarce.
FAQs
-
How can I identify the manufacturer of Cystografin Dilute from the box label?
Check the “Manufacturer” and “Distributed by” lines and match them to the product listing for the exact NDC/presentation.
-
Do Cystografin Dilute products come from contract manufacturers?
Often, with fill-finish and packaging carried out by specialized sites, but the finished-goods manufacturer is the entity listed for the specific NDC.
-
What factors cause supply interruptions for dilute contrast products?
Finished solution manufacturing cycles, packaging capacity, regulatory release timing, and lot disposition.
-
Are there restrictions on swapping Cystografin Dilute with concentrate?
Substitution depends on local protocol and the exact labeling and dilution instructions for the alternative concentration form.
-
Which procurement channel is most reliable for hospitals: GPO or direct distributor?
Reliability is driven by each institution’s contracts; GPO tenders usually define preferred distributor stock, while direct arrangements can improve continuity if they lock inventory.
References (APA)
- No sources were cited because no drug-identifying details (NDC, labeler/manufacturer name, strength, pack configuration, or country) were provided to support a factual supplier list.
